Annovis Bio's Pivotal Alzheimer's Trial Nears Full Enrollment, Receives Positive Safety Recommendation
ANVS sits 38% above its 52-week low of $1.541.
Summary
Annovis Bio reported first-quarter 2026 financial results, showing cash and cash equivalents of $14.2 million as of March 31, 2026, down from $19.5 million, excluding a recent $10.0 million registered direct offering in April. More significantly, the company announced substantial progress in its pivotal Phase 3 Alzheimer's disease (AD) trial for buntanetap, which is now 85% enrolled, with enrollment for new participants closed. The trial also received a positive safety recommendation from the Data and Safety Monitoring Board (DSMB) at 6 months. This update follows the company's recent 10-K filing which highlighted substantial doubt about its ability to continue as a going concern and noted significant shareholder dilution. The strong clinical progress, particularly the near-completion of enrollment and positive safety review for a pivotal AD trial, significantly de-risks the company's lead asset and provides a clear path to top-line data in early 2027. Investors will closely watch the completion of AD trial randomization in summer 2026 and the anticipated symptomatic data readout, which will be critical for potential NDA discussions with the FDA, while also monitoring the company's ongoing cash burn and financing needs.
At the time of this announcement, ANVS was trading at $2.13 on NYSE in the Life Sciences sector, with a market capitalization of approximately $73.6M. The 52-week trading range was $1.54 to $5.50. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.